IP Library › Granted Patent US 7,074,798
Granted Patent B2
US 7,074,798 · App. 10/374,918 · Granted Jul 11, 2006

Xanthine derivative and DPPIV inhibitor

Assignee: Eisai Co., Ltd
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,074,798
App. No.
10/374,918
Granted
Jul 11, 2006
Kind
B2
Abstract

The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect. The compounds are represented by the formula: wherein, m is 0 or 1; n is 0; R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 each represent a hydrogen atom; X represents an alkynyl group, an aryl group, and such, which group may be substituted; and, R 1 and R 2 each independently represents a hydrogen atom, an alkyl group, an alkoxyl group, or such, or salts or hydrates thereof.

Claims (67)

1. A compound represented by the formula (I):

wherein,

R 1 stands for a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a substituted or unsubstituted C 1-6 alkoxy C 1-6 alkyl group, a substituted or unsubstituted C 3-6 alkynyl group, a substituted or unsubstituted C 2-7 cyanoalkyl group, a substituted or unsubstituted C 6-12 aryl C 1-6 alkyl group, a substituted or unsubstituted C 1-12 aryloxy C 1-6 alkyl group, or a group represented by the formula:

wherein,

a denotes 1;

R 5 and R 6 both denote a hydrogen atom; and,

R 7 denotes a hydroxyl group, a substituted or unsubstituted C 1-6 alkoxy group, a substituted or unsubstituted phenyl group, or a group represented by the formula —N(R 3 )R 4 ,

wherein, R 3 and R 4 are identical to or different from each other and individually denote a hydrogen atom, or a substituted or unsubstituted C 1-6 alkyl group;

R 2 stands for a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a substituted or unsubstituted C 1-6 alkoxy C 1-6 alkyl group, a substituted or unsubstituted 3 to 10-membered heterocyclic C 1-6 alkyl group, a substituted or unsubstituted C 6-12 aryl C 1-6 alkyl group, a group represented by the formula:

wherein,

a denotes 1;

R 5 and R 6 are identical to or different from each other and individually denote a hydrogen atom, C 1-6 alkyl group, or phenyl group; and,

R 7 denotes a hydroxyl group, C 1-6 alkyl group, C 1-6 alkoxy group, a substituted or unsubstituted phenyl group, or a group represented by —N(R 3 )R 4 ,

wherein,

R 3 and R 4 are identical to or different from each other and individually denote a hydrogen atom, C 1-6 alkyl group, C 3-7 cycloalkyl group, C 3-6 alkynyl group, or C 6-12 aryl group; or,

R 3 and R 4 may be linked to each other to form a ring containing one or more heteroatoms,

or a group represented by the formula:

wherein Y denotes an oxygen atom, or a group represented by —NR 8 , wherein R 8 denotes a hydrogen atom, or C 1-6 alkyl group; and

X stands for a phenyl group wherein position 2 may have a substituent selected from the group consisting of a hydrogen atom, hydroxyl group, fluorine atom, chlorine atom, methyl group, ethyl group, fluoromethyl group, ethenyl group, methoxy group, ethoxy group, acetyl group, cyano group, formyl group, and C 2-7 aliphaticailcoxy carbonyl group, or a salt thereof.

2. The compound of claim 1 , or a salt thereof, wherein R 1 stands for a hydrogen atom, C 1-6 alkyl group, C alkynyl group, cyanomethyl group, a substituted or unsubstituted benzyl group, a substituted or unsubstituted phenethyl group, a substituted or unsubstituted phenoxyethyl group, or a group represented by the formula:

wherein, a denotes 1;

R 5 and R 6 both denote a hydrogen atom; and,

R 7 denotes a hydroxyl group, C 1-6 alkoxy group, or a substituted or unsubstituted phenyl group.

3. The compound of claim 1 , or a salt thereof, wherein R 1 stands for a hydrogen atom, methyl group, 2-propynyl group, 2-butynyl group, cyanometbyl group, phenethyl group, phenoxyethyl group, or a group represented by the formula:

wherein, a denotes 1;

R 5 and R 6 both denote a hydrogen atom; and,

R 7 denotes a hydroxyl group, C 1-6 alkoxy group, or phenyl group.

4. The compound of claim 1 , or a salt thereof, wherein R 2 stands for a substituted or unsubstituted C 1-6 alkoxy C 1-6 alkyl group, a substituted or unsubstituted 3 to 10-membered heterocyclic C 1-6 alkyl group, a substituted or unsubstituted C 6-12 aryl C 1-6 alkyl group, a group represented by the formula:

wherein,

a denotes 1;

R 5 and R 6 are identical to or different from each other and individually denote a hydrogen atom, C 1-6 alkyl group, or a phenyl group; R 7 denotes a hydroxyl group, C 1-6 alkyl group, C 1-6 alkoxy group, a substituted or unsubstituted phenyl group, or a group represented by the formula —N(R 3 )R 4 ,

wherein,

R 3 and R 4 are identical to or different from each other and individually denote a hydrogen atom, C 1-6 alkyl group, C 3-7 cycloalkyl group, C 3-6 alkynyl group, or C 6-12 aryl group; or,

R 3 and R 4 may be linked to each other to form a ring containing one or more heteroatoms,

or a group represented by the formula:

wherein Y denotes an oxygen atom, or a group represented by —NR 8 , wherein R 8 denotes a hydrogen atom, or a C 1-6 alkyl group.

5. The compound of claim 1 , or a salt thereof, wherein R 2 stands for a hydrogen atom, C 1-6 alkyl group, C 1-6 alkoxy C 1-6 alkyl group, tetrahydrofuranylmethyl group, a substituted or unsubstituted benzyl group, a group represented by the formula:

wherein,

a denotes 1;

R 5 and R 6 are identical to or different from each other and individually denote a hydrogen atom, C 1-6 alkyl group, or a phenyl group; and,

R 7 denotes a hydroxyl group, C 1-6 alkyl group, C 1-6 alkoxy group, a substituted or unsubstituted phenyl group, or a group represented by the formula —N(R 3 )R 4 ,

wherein,

R 3 and R 4 are identical to or different from each other and individually denote a hydrogen atom, or a C 1-6 alkyl group,

or a group represented by the formula:

wherein Y denotes an oxygen atom, or —NR 8 , wherein R 8 denotes a hydrogen atom, or C 1-6 alkyl group.

6. The compound of claim 1 , or a salt thereof, wherein R 2 stands for a C 1-6 alkoxy C 1-6 alkyl group, tetrahydrofuranylmethyl group, a substituted or unsubstituted benzyl group, a group represented by the formula:

wherein,

a denotes 1; and,

R 5 and R 6 are identical to or different from each other and individually denote a hydrogen atom, C 1-6 alkyl group, or a phenyl group; R 7 denotes a hydroxyl group, C 1-6 alkyl group, C 1-6 alkoxy group, a substituted or unsubstituted phenyl group, or a group represented by the formula —N(R 3 )R 4 ,

wherein,

R 3 and R 4 are identical to or different from each other and individually denote a hydrogen atom, or C 1-6 alkyl group,

or a group represented by the formula:

wherein Y denotes an oxygen atom, or —NR 8 , wherein R 8 denotes a hydrogen atom, or C 1-6 alkyl group.

7. The compound of claim 1 , or a salt thereof, wherein R 2 stands for a hydrogen atom, C 1-6 alkyl group, ethoxyethyl group, tetrahydrofuranylmethyl group, a group represented by the formula:

wherein,

a denotes 1;

R 5 and R 6 are identical to or different from each other and individually denote a hydrogen atom, methyl group, or phenyl group; and,

R 7 denotes a hydroxyl group, C 1-6 alkoxy group, or phenyl group.

or a group represented by the formula:

wherein Y denotes —NR 8 wherein R 8 denotes a hydrogen atom.

8. The compound of claim 1 , or a salt thereof, wherein R 2 stands for an ethoxyethyl group, tetrahydrofuranylmethyl group, a group represented by the formula:

wherein,

a denotes 1;

R 5 and R 6 are identical to or different from each other and individually denote a hydrogen atom, methyl group, or phenyl group; and,

R 7 denotes a hydroxyl group, C 1-6 alkoxy group, or phenyl group, or a group represented by the formula:

wherein Y denotes —NR 8 , wherein R 8 denotes a hydrogen atom.

9. A pharmaceutical composition comprising a compound of claim 1 , or a salt thereof, and a pharmaceutically acceptable excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2007
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 019265/0447 →
Priority Claims (2)
JP 2002-047761 · Feb 25, 2002 · national
JP 2002-149557 · May 23, 2002 · national
Continuity (1)
Related Publication 20040082570A1 · Apr 29, 2004